Monday, November 2, 2026Moscow
Economy

Vetbiohim suspends production of Multican animal vaccine

Production of all batches of the Multicane vaccine has been suspended. This was reported by RIA Novosti in Vetbiokhim.

Published

Production of all batches of the Multicane vaccine has been suspended. This was reported by RIA Novosti in Vetbiokhim. Earlier, the Rosselkhoznadzor found in the samples of the vaccine the deadly Auieska virus and ordered to suspend the treatment of several batches of the drug. Vetbiohim is working with owners of animals killed and injured by the vaccine, the company said.

The head of the Rosselkhoznadzor Sergey Dankvert reported at least 300 cases of dog deaths after vaccination with Multican. According to him, serious violations of technology were committed during the production of the drug. The Rosselkhoznadzor has suspended the appeal of Multikan-8 series No. 20, 21, and Multikan-6 series No. 11 and 12.

More in the material “Kommersant” “Dog business of each”.

Source: Коммерсантъ ↗

Share

More on This Story

EconomyThe Ministry of Finance from October 7 will increase the purchase of currency and gold five times

The Ministry of Finance of Russia from October 7 to November 6 intends to buy foreign currency and gold under the budget rule for 279.42 billion rubles. This is five times more than the volume planned a month earlier (55.6 billion rubles).

Коммерсантъ
EconomyThe FT learned how the growing debt burden prevents China from stimulating the economy

China’s debt service will cost 19.2 percent of total government this year, according to a study by the Conference Board

Григорий Лебедев
The head of JPMorgan said that the Russian army could reach Paris if desired
EconomyThe head of JPMorgan said that the Russian army could reach Paris if desired

Dimon said that EU countries cannot afford full-fledged armies and the Russian Armed Forces could reach Paris if desired. The US should support the EU and make more deals with it to avoid fragmentation

Григорий Лебедев
The EIA Briefing

Keep reading, every morning.

The stories that matter, chosen by our editors and in your inbox before 7 a.m. — every weekday.

No spam. Unsubscribe anytime.